From peptides to small molecules: An intriguing but intricated way to new drugs

Current Medicinal Chemistry

Volumn 20, Issue 31, 2013, Pages 3803-3817

  Scognamiglio, P L ^a   Di Natale, C ^a   Perretta, G ^b   Marasco, D ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CNR   (Italy)

Author keywords

Molecular Interaction; Peptides as drugs; Small molecules

Indexed keywords

6 O CYCLOHEXYLMETHYLGUANINE; AMINO ACID; ANTIINFECTIVE AGENT; CANCER VACCINE; ENFUVIRTIDE; EPTIFIBATIDE; EXENDIN 4; GASTRIN 17; GLATIRAMER; GOSERELIN; HIRULOG; LEUPRORELIN; LINACLOTIDE; LUCINACTANT; MONOCLONAL ANTIBODY; NU 2958; OCTREOTIDE; PEGINESATIDE; PEPTIDE; PEPTIDOMIMETIC AGENT; PHOSPHOTRANSFERASE INHIBITOR; POLYPEPTIDE; POLYPEPTIDE ANTIBIOTIC AGENT; SALCATONIN; SMALL MOLECULE TRANSPORT AGENT; TEDUGLUTIDE; TRIPTORELIN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; BINDING AFFINITY; BIOAVAILABILITY; CELL CULTURE; CHEMICAL BOND; CLINICAL TRIAL; CYCLIZATION; DRUG INDUSTRY; DRUG RECEPTOR BINDING; GASTROINTESTINAL TUMOR; HIGH THROUGHPUT SCREENING; IC 50; MELANOMA; MOLECULAR INTERACTION; NONHUMAN; PANCREAS CANCER; PHAGE DISPLAY; PHARMACOPHORE; PROTEIN MOTIF; PROTEIN STRUCTURE; STOMACH CANCER; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; ANIMALS; DRUG DISCOVERY; HUMANS; PEPTIDES;

EID: 84887918731     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/09298673113209990184     Document Type: Article

References (100)

1. Audie, J.; Boyd, C. The synergistic use of computation, chemistry and biology to discover novel peptide-based drugs: the time is right. Curr. Pharm. Des., 2010, 16(5), 567-582.
2. Loffet, A. Peptides as drugs: is there a market? J. Pept. Sci., 2002, 8(1), 1-7.
3. Loregian, A.; Palu, G. Disruption of protein-protein interactions: towards new targets for chemotherapy. J. Cell. Physiol., 2005, 204(3), 750-762.
4. Braun, P.; Gingras, A.C. History of protein-protein interactions: from egg-white to complex networks. Proteomics, 2012, 12(10), 1478-1498.
5. Pellecchia, M. Antagonists of protein-protein interactions made easy? J. Med. Chem., 2013, 56(1), 13-14.
6. Vagner, J.; Qu, H.; Hruby, V.J. Peptidomimetics, a synthetic tool of drug discovery. Curr. Opin. Cell. Biol., 2008, 12(3), 292-296.
7. Henkin, R.I. Intranasal insulin: from nose to brain. Nutrition, 2010, 26(6), 624-633.
8. Nielsen, C.U.; Brodin, B. Di/tri-peptide transporters as drug delivery targets: regulation of transport under physiological and pathophysiological conditions. Curr. Drug Targets, 2003, 4(5), 373-388.
9. Baltzer, L. Crossing borders to bind proteins-a new concept in protein recognition based on the conjugation of small organic molecules or short peptides to polypeptides from a designed set. Anal. Bioanal. Chem., 2011, 400(6), 1653-1664.
10. Lee, K.H. Discovery and development of natural product-derived chemotherapeutic agents based on a medicinal chemistry approach. J. Nat. Prod., 2010, 73(3), 500-516.
11. Hutchinson, C.R. Combinatorial biosynthesis for new drug discovery. Curr. Opin. Microbiol., 1998, 1(3), 319-329.
12. Cane, D.E.; Walsh, C.T.; Khosla, C. Harnessing the biosynthetic code: combinations, permutations, and mutations. Science, 1998, 282(5386), 63-68.
13. Ng, J.H.; Ilag, L.L. Cryptic protein fragments as an emerging source of peptide drugs. IDrugs, 2006, 9(5), 343-346.
14. Sizonenko, S.V.; Sirimanne, E.S.; Williams, C.E.; Gluckman, P.D. Neuroprotective effects of the N-terminal tripeptide of IGF-1, glycine-proline-glutamate, in the immature rat brain after hypoxicischemic injury. Brain Res., 2001, 922(1), 42-50.
15. Reynolds, E.C. Anticariogenic complexes of amorphous calcium phosphate stabilized by casein phosphopeptides: a review. Spec. Care Dentist, 1998, 18(1), 8-16.
16. Autelitano, D.J.; Rajic, A.; Smith, A.I.; Berndt, M.C.; Ilag, L.L.; Vadas, M. The cryptome: a subset of the proteome, comprising cryptic peptides with distinct bioactivities. Drug Discov. Today, 2006, 11(7-8), 306-314.
17. Bruckdorfer, T.; Marder, O.; Albericio, F. From production of peptides in milligram amounts for research to multi-tons quantities for drugs of the future. Curr. Pharm. Biotechnol., 2004, 5(1), 29-43.
18. Lee, J.Y.; Bang, D. Challenges in the chemical synthesis of average sized proteins: sequential vs. convergent ligation of multiple peptide fragments. Biopolymers, 2010, 94(4), 441-447.
19. Doti, N.; Cassese, A.; Marasco, D.; Paturzo, F.; Sabatella, M.; Viparelli, F.; Dathan, N.; Monti, S.M.; Miele, C.; Formisano P.; Beguinot, F.; Ruvo, M. Residues 762-801 of PLD1 mediate the interaction with PED/PEA15. Mol. Biosyst., 2008, 6(10), 2039-2048.
20. Marasco, D.; Stilo, R.; Sandomenico, A.; Monti, S.M.; Tizzano, B.; de Capua, A.; Varricchio, E.; Liguoro, D.; Zotti, T.; Formisano, S.; Ruvo, M.; Vito, P. Generation and functional characterization of a BCL10-inhibitory peptide that represses NF-kappaB activation. Biochem. J., 2009, 422(3), 553-561.
21. Viparelli, F.; Cassese, A.; Doti, N.; Paturzo, F.; Marasco, D.; Dathan, N.A.; Monti, S.M.; Basile G.; Ungaro P.; Sabatella M.; Miele C.; Teperino R.; Consiglio E.; Pedone C.; Beguinot F.; Formisano, P.; Ruvo, M. Targeting of PED/PEA-15 molecular interaction with phospholipase D1 enhances insulin sensitivity in skeletal muscle cells. J. Biol. Chem., 2008, 283(31), 21769-21778.
22. Vitagliano, L.; Fiume, G.; Scognamiglio, P.L.; Doti, N.; Cannavo, R.; Puca, A.; Pedone, C.; Scala, G.; Quinto, I.; Marasco, D. Structural and functional insights into IkappaB-alpha/HIV-1 Tat interaction. Biochimie, 2011, 93(9), 1592-1600.
23. Causa, F.; Della Moglie, R.; Iaccino, E.; Mimmi, S.; Marasco, D.; Scognamiglio, P.L.; Battista, E.; Palmieri, C.; Cosenza, C.; Sanguigno, L.; Quinto, I.; Scala, G.; Netti, PA. Evolutionary screening and adsorption behavior of engineered M13 bacteriophage and derived dodecapeptide for selective decoration of gold interfaces. J. Colloid Interface Sci., 2013, 389(1), 220-229.
24. Scott, J.K.; Smith, G.P. Searching for peptide ligands with an epitope library. Science, 1990, 249(4967), 386-390.
25. Weiner, R.E.; Thakur, M.L. Radiolabeled peptides in the diagnosis and therapy of oncological diseases. Appl. Radiat. Isot., 2002, 57(5), 749-763.
26. Marasco, D.; Perretta, G.; Sabatella, M.; Ruvo, M. Past and future perspectives of synthetic peptide libraries. Curr. Protein Pept. Sci., 2008, 9(5), 447-467.
27. Ponticelli, S.; Marasco, D.; Tarallo, V.; Albuquerque, R.J.; Mitola, S.; Takeda, A.; Stassen, J.M.; Presta, M.; Ambati, J.; Ruvo, M.; De Falco, S. Modulation of angiogenesis by a tetrameric tripeptide that antagonizes vascular endothelial growth factor receptor 1. J. Biol. Chem. 2008, 283(49), 34250-34259.
28. Lonardo, E.; Parish, C.L.; Ponticelli, S.; Marasco, D.; Ribeiro, D.; Ruvo, M., De Falco, S.; Arenas, E.; Minchiotti, G. A small synthetic cripto blocking Peptide improves neural induction, dopaminergic differentiation, and functional integration of mouse embryonic stem cells in a rat model of Parkinson's disease. Stem. Cells, 2010, 28(8), 1326-1337.
29. Lam, K.S.; Salmon, S.E.; Hersh, E.M.; Hruby, V.J.; Kazmierski, W.M., Knapp, R.J. A new type of synthetic peptide library for identifying ligand-binding activity. Nature, 1991, 354(6348), 82-84.
30. Appel, J.R.; Buencamino, J.; Houghten, R.A.; Pinilla, C. Exploring antibody polyspecificity using synthetic combinatorial libraries. Mol. Divers., 1996, 2(1-2), 29-34.
31. Liskamp, R.M.; Rijkers, D.T.; Kruijtzer, J.A.; Kemmink, J. Peptides and proteins as a continuing exciting source of inspiration for peptidomimetics. Chembiochem., 2011, 12(11), 1626-1653.
32. Scognamiglio, P.L.; Doti, N.; Grieco, P.; Pedone, C.; Ruvo, M.; Marasco, D. Discovery of small peptide antagonists of PED/PEA15-D4alpha interaction from simplified combinatorial libraries. Chem. Biol. Drug Des., 2011, 77(5), 319-327.
33. Leone, M.; Freeze, H.H.; Chan, C.S.; Pellecchia, M. The Nuclear Overhauser Effect in the lead identification process. Curr. Drug Discov. Technol., 2006, 3(2), 91-100.
34. Pennington, M.W.; Dunn, B.M. Peptide Synthesis Protocols. Met. Mol. Biol. 1995.
35. Kazmaier U.; Persch A. A straightforward approach towards 5-substituted thiazolylpeptides via the thio-Ugi-reaction. Org. Biomol. Chem., 2010, 8(23), 5442-5447.
36. Cressina, E.; Lloyd, A.J.; De Pascale, G.; James Mok, B.; Caddick, S.; Roper, D.I.; Dowson C.G.; Bugg, T.D. Inhibition of tRNAdependent ligase MurM from Streptococcus pneumoniae by phosphonate and sulfonamide inhibitors. Bioorg. Med. Chem., 2009, 17(9), 3443-3455.
37. Hoffman, R.V.; Tao, J. A simple, stereoselective synthesis of ketomethylene dipeptide isosteres. Tetrahedron, 1997, 53(21), 7119-7126.
38. Fletcher M.M.; Campbell, M.M. Partially Modified Retro-Inverso Peptides: Development, Synthesis, and Conformational Behavior. Chem. Rev., 1998, 98(2), 763-796.
39. Crozet, Y.; Wen, J.J.; Loo, R.O.; Andrews, P.C.; Spatola, A.F. Synthesis and characterization of cyclic pseudopeptide libraries containing thiomethylene and thiomethylene-sulfoxide amide bond surrogates. Mol. Divers., 1997-1998, 3(4), 261-276.
40. Rodriguez, M.; Heitz, A.; Martinez, J. "Carba" peptide bond surrogates: synthesis of Boc-L-Leu-(CH2-CH2)-L-Phe-OH and Boc-LLeu-(CH2-CH2)-D- Phe-OH through a horner-emmons reaction. Tetrahedron Lett., 1990, 30(50), 7319-7322.
41. Pégorier, L.; Larchevêque, M. A general stereocontrolled synthesis of hydroxyethylene dipeptide isosteres. Tetrahedron Lett., 1995, 36(16), 2753-2756.
42. Norman, B.H.; Kroin, J.S. Alkylation studies of N-protected-5-substituted morpholin-3-ones. A stereoselective approach to novel methylene ether dipeptide isosteres. J. Org. Chem., 1996, 61, 4990-4998.
43. Hill, R.B.; Raleigh, D.P.; Lombardi, A.; DeGrado, W.F. De novo design of helical bundles as models for understanding protein folding and function. Acc. Chem. Res., 2000, 33(11), 45-54.
44. Pajouhesh, H.; Lenz, G.R. Medicinal chemical properties of successful central nervous system drugs. NeuroRx, 2005, 2(4), 541-553.
45. Welch, B.D.; Van Demark, A.P.; Heroux, A.; Hill, C.P.; Kay, M.S. Potent D-peptide inhibitors of HIV-1 entry. Proc. Natl. Acad. Sci. USA, 2007, 104(43), 16828-16833.
46. Khedkar, S.A.; Malde, A.K.; Coutinho, E.C.; Srivastava, S. Pharmacophore modeling in drug discovery and development: an overview. J. Med. Chem., 2007, 3(2), 187-197.
47. Zou, J.; Xie, H.Z.; Yang, S.Y.; Chen, J.J.; Ren, J.X.; Wei, Y.Q. Towards more accurate pharmacophore modeling: Multicomplexbased comprehensive pharmacophore map and most-frequentfeature pharmacophore model of CDK2. J. Mol. Graph. Model., 2008, 27(4), 430-438.
48. Tintori, C.; Manetti, F.; Botta, M. Pharmacophoric models and 3D QSAR studies of the adenosine receptor ligands. Curr. Top. Med. Chem., 2010, 10(10), 1019-1035.
49. Shang, X.; Marchioni, F.; Evelyn, C.R.; Sipes, N.; Zhou, X.; Seibel, W.; Wortman, M.; Zheng, Y. Small-molecule inhibitors targeting G-protein-coupled Rho guanine nucleotide exchange factors. Proc. Natl. Acad. Sci. USA, 2013, 110(8), 3155-3160.
50. Morikis, D.; Floudas, C.A.; Lambris, J.D. Structure-Based Integrative Computational and Experimental Approach for the Optimization of Drug Design. Comp. Sci., 2005, 3515, 680-688.
51. Dror, O.; Schneidman-Duhovny, D.; Inbar, Y.; Nussinov, R.; Wolfson, H.J. Novel approach for efficient pharmacophore-based virtual screening: method and applications. J. Chem. Inf. Model., 2009, 49(10), 2333-2343.
52. Sillerud, L.O.; Larson, R.S. Design and structure of peptide and peptidomimetic antagonists of protein-protein interaction. Curr. Protein Pept. Sci., 2005, 6(2), 151-169.
53. Watt, P.M. Screening for peptide drugs from the natural repertoire of biodiverse protein folds. Nat. Biotechnol., 2006, 24(2), 177-183.
54. Flohr, S.; Kurz, M.; Kostenis, E.; Brkovich, A.; Fournier, A.; Klabunde, T. Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II. J. Med. Chem., 2002, 45(9), 1799-1805.
55. Landon, L.A.; Deutscher, S.L. Combinatorial discovery of tumor targeting peptides using phage display. J. Cell. Biochem., 2003, 90(3), 509-517.
56. Landon, L.A.; Zou, J.; Deutscher, S.L. Is phage display technology on target for developing peptide-based cancer drugs? Curr. Drug Discov. Technol., 2004, 1(2), 113-132.
57. Zitzmann, S.; Mier, W.; Schad, A.; Kinscherf, R.; Askoxylakis, V.; Kramer, S.; Altmann, A.; Eisenhut, M.; Haberkorn, U. A new prostate carcinoma binding peptide (DUP-1) for tumor imaging and therapy. Clin. Cancer Res., 2005, 11(1), 139-146.
58. Falciani, C.; Lozzi, L.; Pini, A.; Bracci, L. Bioactive peptides from libraries. Chem. Biol., 2005, 12(4), 417-426.
59. Pini, A.; Giuliani, A.; Falciani, C.; Runci, Y.; Ricci, C.; Lelli, B.; Malossi, M.; Neri, P.; Rossolini, G.M.; Bracci, L. Antimicrobial activity of novel dendrimeric peptides obtained by phage display selection and rational modification. Antimicrob. Agents Chemother., 2005, 49(7), 2665-2672.
60. Su, J.L.; Lai, K.P.; Chen, C.A.; Yang, C.Y.; Chen, P.S.; Chang, C.C.; Chou, C.H.; Hu, C.L.; Kuo, M.L.; Hsieh, C.Y. A novel peptide specifically binding to interleukin-6 receptor (gp80) inhibits angiogenesis and tumor growth. Cancer Res., 2005, 65(11), 4827-4835.
61. Mezo, A.R.; McDonnell, K.A.; Hehir, C.A.; Low, S.C.; Palombella, V.J.; Stattel, J.M.; Kamphaus, G.D.; Fraley, C.; Zhang, Y.; Dumont, J.A.; Bitonti, A.J. Reduction of IgG in nonhuman primates by a peptide antagonist of the neonatal Fc receptor FcRn. Proc. Natl. Acad. Sci. USA, 2008, 105(7), 2337-2342.
62. Sugahara, K.N.; Teesalu, T.; Karmali, P.P.; Kotamraju, V.R.; Agemy, L.; Greenwald, D.R.; Ruoslahti, E. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science, 2010, 328(5981), 1031-1035.
63. Aina, O.H.; Sroka, T.C.; Chen, M.L.; Lam, K.S. Therapeutic cancer targeting peptides. Biopolymers, 2002, 66(3), 184-199.
64. Peng, L.; Liu, R.; Marik, J.; Wang, X.; Takada, Y.; Lam, K.S. Combinatorial chemistry identifies high-affinity peptidomimetics against alpha4beta1 integrin for in vivo tumor imaging. Nat. Chem. Biol., 2006, 2(7), 381-389.
65. Yang, J.T.; Rayburn, H.; Hynes, R.O. Cell adhesion events mediated by alpha 4 integrins are essential in placental and cardiac development. Development, 1995, 121(2), 549-560.
66. Holzmann, B.; Gosslar, U.; Bittner, M. Alpha 4 integrins and tumor metastasis. Curr. Top. Microbiol. Immunol., 1998, 231, 125-141.
67. Vincent, A.M.; Cawley, J.C.; Burthem, J. Integrin function in chronic lymphocytic leukemia. Blood, 1996, 87(11), 4780-4788.
68. Marco, R.A.; Diaz-Montero, C.M.; Wygant, J.N.; Kleinerman, E.S.; McIntyre, B.W. Alpha 4 integrin increases anoikis of human osteosarcoma cells. J. Cell. Biochem., 2003, 88(5), 1038-1047.
69. Damiano, J.S.; Dalton, W.S. Integrin-mediated drug resistance in multiple myeloma. Leuk. Lymphoma, 2000, 38(1-2), 71-81.
70. Matsunaga, T.; Takemoto, N.; Sato, T.; Takimoto, R.; Tanaka, I.; Fujimi, A.; Akiyama, T.; Kuroda, H.; Kawano, Y.; Kobune, M.; Kato, J.; Hirayama, Y.; Sakamaki, S.; Kohda, K.; Miyake, K.; Niitsu, Y. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat. Med., 2003, 9(9), 158-165.
71. Doti, N.; Scognamiglio, P.L.; Madonna, S.; Scarponi, C.; Ruvo, M.; Perretta, G.; Albanesi, C.; Marasco, D. New mimetic peptides of the kinase-inhibitory region (KIR) of SOCS1 through focused peptide libraries. Biochem. J., 2012, 443(1), 231-240.
72. Madonna, S.; Scarponi, C.; Doti, N.; Carbone, T.; Cavani, A.; Scognamiglio, P.L.; Marasco, D.; Albanesi, C. Therapeutical potential of a peptide mimicking the SOCS1 kinase inhibitory region in skin immune responses, Eur. J. Immun., 2013, in press.
73. Timmerman, P.; Barderas, R.; Desmet, J.; Altschuh, D.; Shochat, S.; Hollestelle, M.J.; Hoppener, J.W.; Monasterio, A.; Casal, J.I.; Meloen, R.H. A combinatorial approach for the design of complementarity-determining region-derived peptidomimetics with in vitro anti-tumoral activity. J. Biol. Chem., 2009, 284(49), 34126-34134.
74. Adams, G.P.; Weiner, L.M. Monoclonal antibody therapy of cancer. Nat. Biotechnol., 2005, 23(9), 1147-1157.
75. Carter, P.J. Potent antibody therapeutics by design. Nat. Rev. Immunol., 2006, 6(5), 343-357.
76. Reichert, J.M.; Rosensweig, C.J.; Faden, L.B.; Dewitz, M.C. Monoclonal antibody successes in the clinic. Nat. Biotechnol., 2005, 23(9), 1073-1078.
77. Casset, F.; Roux, F.; Mouchet, P.; Bes, C.; Chardes, T.; Granier, C.; Mani, J.C.; Pugniere, M.; Laune, D.; Pau, B.; Kaczorek, M.; Lahana, R.; Rees, A. A peptide mimetic of an anti-CD4 monoclonal antibody by rational design. Biochem. Biophys. Res. Commun., 2003, 307(1), 198-205.
78. Laune, D.; Molina, F.; Mani, J.; Del Rio, M.; Bouanani, M.; Pau, B.; Granier, C. Dissection of an antibody paratope into peptides discloses the idiotope recognized by the cognate anti-idiotypic antibody. J. Immunol. Methods, 2000, 239(1-2), 63-73.
79. Takasaki, W.; Kajino, Y.; Kajino, K.; Murali, R.; Greene, M.I. Structure-based design and characterization of exocyclic peptidomimetics that inhibit TNF alpha binding to its receptor. Nat. Biotechnol., 1997, 15(12), 1266-1270.
80. Gilliam, A.D.; Watson, S.A.; Henwood, M.; McKenzie, A.J.; Humphreys, J.E.; Elder, J.; Iftikhar, S.Y.; Welch, N.; Fielding, J.; Broome, P.; Michaeli, D. A phase II study of G17DT in gastric carcinoma. Eur. J. Surg. Oncol., 2004, 30(5), 536-543.
81. Brett, B.T.; Smith, S.C.; Bouvier, C.V.; Michaeli, D.; Hochhauser, D.; Davidson, B.R.; Kurzawinski, T.R.; Watkinson, A.F.; Van Someren, N.; Pounder, R.E.; Caplin, M.E. Phase II study of antigastrin-17 antibodies, raised to G17DT, in advanced pancreatic cancer. J. Clin. Oncol., 2002, 20(20), 4225-4231.
82. Gilliam, A.D.; Watson, S.A. G17DT: an antigastrin immunogen for the treatment of gastrointestinal malignancy. Expert. Opin. Biol. Ther., 2007, 7(3), 397-404.
83. Yu, H.G.; Schrader, H.; Otte, J.M.; Schmidt, W.E.; Schmitz, F. Rapid tyrosine phosphorylation of focal adhesion kinase, paxillin, and p130Cas by gastrin in human colon cancer cells. Biochem. Pharmacol., 2004, 67(1), 135-146.
84. Tan, M.H.; Nowak, N.J.; Loor, R.; Ochi, H.; Sandberg, A.A.; Lopez, C.; Pickren, J.W.; Berjian, R.; Douglass, H.O.; Jr. Chu, T.M. Characterization of a new primary human pancreatic tumor line. Cancer Invest., 1986, 4(1), 15-23.
85. Barderas, R.; Shochat, S.; Timmerman, P.; Hollestelle, M.J.; Martinez-Torrecuadrada, J.L.; Hoppener, J.W.; Altschuh, D.; Meloen, R.; Casal, J.I. Designing antibodies for the inhibition of gastrin activity in tumoral cell lines. Int. J. Cancer, 2008, 122(10), 2351-2359.
86. Rathinakumar, R.; Walkenhorst, W.F.; Wimley, W.C. Broadspectrum antimicrobial peptides by rational combinatorial design and high-throughput screening: the importance of interfacial activity. J. Am. Chem. Soc., 2009, 131(22), 7609-7617.
87. He, J.; Eckert, R.; Pharm, T.; Simanian, M.D.; Hu, C.; Yarbrough, D.K.; Qi, F.; Anderson, M.H., Shi, W. Novel synthetic antimicrobial peptides against Streptococcus mutans. Antimicrob. Agents Chemother., 2007, 51(4), 1351-1358.
88. Cirillo, D.; Pentimalli, F.; Giordano, A. Peptides or small molecules? Different approaches to develop more effective CDK inhibitors. Curr. Med. Chem., 2011, 18(19), 2854-2866.
89. Orzaez, M.; Gortat, A.; Mondragon, L.; Bachs, O.; Perez-Paya, E. ATP-noncompetitive inhibitors of CDK-cyclin complexes. Chem. Med. Chem., 2009, 4(1), 19-24.
90. Arris, C.E.; Boyle, F.; Calvert, A.H.; Curtin, N.J.; Endicott, J.A.; Garman, E.F.; Gibson, A.E.; Golding, B.T.; Grant, S.; Griffin, R.J.; Jewsbury, P.; Johnson, L.N.; Lawrie, A.M.; Newell, D.R.; Noble, M.E., Sausville, E.A.; Schultz, R.; Yu; W. Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. J. Med. Chem., 2000, 43(15), 2797-2804.
91. Bagella, L.; Sun, A.; Tonini, T.; Abbadessa, G.; Cottone, G.; Paggi, M.G.; De Luca, A.; Claudio, P.P.; Giordano, A. A small molecule based on the pRb2/p130 spacer domain leads to inhibition of cdk2 activity, cell cycle arrest and tumor growth reduction in vivo. Oncogene, 2007, 26(13), 1829-1839.
92. Anthony, L.; Freda, P.U. From somatostatin to octreotide LAR: evolution of a somatostatin analogue. Curr. Med. Res. Opin., 2009, 25(12), 2989-2999.
93. Douat-Casassus, C.; Marchand-Geneste, N.; Diez, E.; Aznar, C.; Picard, P.; Geoffre, S.; Huet, A.; Bourguet-Kondracki, M.L.; Gervois, N.;Jotereau, F. Covalent modification of a melanoma-derived antigenic peptide with a natural quinone methide. Preliminary chemical, molecular modelling and immunological evaluation studies. Mol. Biosyst., 2006, 2(5), 240-249.
94. Bray, BL. Large-scale manufacture of peptide therapeutics by chemical synthesis. Nat. Rev. Drug Discov., 2003, 2(7), 587-593.
95. Rotem, S.; Mor, A. Antimicrobial peptide mimics for improved therapeutic properties. Biochim. Biophys. Acta, 2009, 1788(8), 1582-1592.
96. Banks, W.A.; Gertler, A.; Solomon, G.; Niv-Spector, L.; Shpilman, M.; Yi X.; Batrakova, E.; Vinogradov, S.; Kabanov, A.V. Principles of strategic drug delivery to the brain (SDDB): development of anorectic and orexigenic analogs of leptin. Physiol. Behav., 2011, 105(1), 145-149.
97. Noble, S.L.; Johnston, E.; Walton, B. Insulin lispro: a fast-acting insulin analog. Am. Fam. Physician, 1998, 57(2), 279-286, 289-292.
98. du Plessis, L.H.; Kotze, A.F.; Junginger, H.E. Nasal and rectal delivery of insulin with chitosan and N-trimethyl chitosan chloride. Drug Deliv., 2010, 17(6), 399-407.
99. Niu, J.; Huang, A.; Xiao, Y.; Su, Z.; Li, H.; Ping, Q.; Bao, X.; Li, S.; Chen, Y.; Sun, M. Octreotide-mediated tumor cell uptake and intracellular pH-responsive drug delivery of the self-assembly supramolecular nanocarrier. J. Drug Target, 2013, in press.
100. Craik, D.J.; Fairlie, D.P.; Liras, S.; Price, D. The Future of Peptidebased Drugs. Chem. Biol. Drug Des., 2013, 81, 136-147.